ClonoScreen3D - A Novel 3-Dimensional Clonogenic Screening Platform for Identification of Radiosensitizers for Glioblastoma

Mark R Jackson; Amanda R Richards; Abdul-Basit Ayoola Oladipupo; Sandeep K Chahal; Seamus Caragher; Anthony J Chalmers; Natividad Gomez-Roman

doi:10.1016/j.ijrobp.2024.02.046

ClonoScreen3D - A Novel 3-Dimensional Clonogenic Screening Platform for Identification of Radiosensitizers for Glioblastoma

Int J Radiat Oncol Biol Phys. 2024 Mar 16:S0360-3016(24)00355-9. doi: 10.1016/j.ijrobp.2024.02.046. Online ahead of print.

Authors

Mark R Jackson¹, Amanda R Richards¹, Abdul-Basit Ayoola Oladipupo¹, Sandeep K Chahal¹, Seamus Caragher², Anthony J Chalmers¹, Natividad Gomez-Roman³

Affiliations

¹ Wolfson Wohl Cancer Research Centre, School of Cancer Sciences, University of Glasgow, Glasgow, UK.
² Wolfson Wohl Cancer Research Centre, School of Cancer Sciences, University of Glasgow, Glasgow, UK; Division of Plastic and Reconstructive Surgery, Department of Surgery, Massachusetts General Hospital, Massachussetts, USA.
³ Wolfson Wohl Cancer Research Centre, School of Cancer Sciences, University of Glasgow, Glasgow, UK; Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK. Electronic address: natividad.gomez-roman@strath.ac.uk.

PMID: 38493899
DOI: 10.1016/j.ijrobp.2024.02.046

Abstract

Purpose: Glioblastoma (GBM) is a lethal brain tumor. Standard-of-care treatment comprising surgery, radiation, and chemotherapy results in median survival rates of 12 to 15 months. Molecular-targeted agents identified using conventional 2-dimensional (2D) in vitro models of GBM have failed to improve outcome in patients, rendering such models inadequate for therapeutic target identification. A previously developed 3D GBM in vitro model that recapitulates key GBM clinical features and responses to molecular therapies was investigated for utility for screening novel radiation-drug combinations using gold-standard clonogenic survival as readout.

Methods and materials: Patient-derived GBM cell lines were optimized for inclusion in a 96-well plate 3D clonogenic screening platform, ClonoScreen3D. Radiation responses of GBM cells in this system were highly reproducible and comparable to those observed in low-throughout 3D assays. The screen methodology provided quantification of candidate drug single agent activity (half maximal effective concentration or EC₅₀) and the interaction between drug and radiation (radiation interaction ratio).

Results: The poly(ADP-ribose) polymerase inhibitors talazoparib, rucaparib, and olaparib each showed a significant interaction with radiation by ClonoScreen3D and were subsequently confirmed as true radiosensitizers by full clonogenic assay. Screening a panel of DNA damage response inhibitors revealed the expected propensity of these compounds to interact significantly with radiation (13/15 compounds). A second screen assessed a panel of compounds targeting pathways identified by transcriptomic analysis and demonstrated single agent activity and a previously unreported interaction with radiation of dinaciclib and cytarabine (radiation interaction ratio 1.28 and 1.90, respectively). These compounds were validated as radiosensitizers in full clonogenic assays (sensitizer enhancement ratio 1.47 and 1.35, respectively).

Conclusions: The ClonoScreen3D platform was demonstrated to be a robust method to screen for single agent and radiation-drug combination activity. Using gold-standard clonogenicity, this assay is a tool for identification of radiosensitizers. We anticipate this technology will accelerate identification of novel radiation-drug combinations with genuine translational value.